A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors Biogen
- 07 Jun 2017 Biomarkers information updated
- 16 Jan 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Nov 2008 New trial record.